Breaking barriers and moving forward: Reflections on impact and future directions for CGT
By Lung-I Cheng
The ThinkLive Cell and Gene Therapy Summit 2024 culminated in a dynamic fireside chat focusing on the future of cell and gene therapy (CGT).
We were pleased to welcome Rita Johnson-Greene, Chief Operating Officer, Alliance for Regenerative Medicine (ARM), to delve into overcoming obstacles in the CGT domain, and exploring strategies to empower patients and enhance access.
Sharing perspectives on the evolving CGT landscape over the next few years, Mrs. Johnson-Greene explored the significant strides made in gene therapy approvals in 2024, underlining the maturation of regenerative medicine through increased competition among therapies targeting various diseases. She emphasized competition and globalization as key drivers for innovation, leading to lower costs and expanded patient access.
Sharing perspectives on the evolving CGT landscape over the next few years, Mrs. Johnson-Greene explored the significant strides made in gene therapy approvals in 2024, underlining the maturation of regenerative medicine through increased competition among therapies targeting various diseases. She emphasized competition and globalization as key drivers for innovation, leading to lower costs and expanded patient access.
Industrialization and advancements in manufacturing were identified as crucial factors in scaling up CGTs effectively, with the importance of embracing new technologies to streamlined processes and deliver life-changing medicines on a larger scale. The conversation also underscored collaboration among stakeholders as key to advancing patient empowerment and access globally.
Fill out the form below to watch the full recording for deeper insights into the transformative world of CGT.
Pardot Form
A glimpse into the future of CGTs with ARM’s Rita Johnson-Greene
Breakthroughs with cell and gene therapy innovation are transforming the therapeutic landscape, with a number of approvals in the US and EU and more in the pipeline. This issue has been top of mind during many sessions throughout Cencora’s two-day ThinkLive CGT Summit. In this impactful meeting, Cencora’s Lung-I Cheng, Ph.D., Vice President and Head of Cell and Gene Therapy, joined Rita Johnson-Greene, Chief Operating Officer, Alliance for Regenerative Medicine (ARM) to reflect on the current and future state of CGT innovation.
Topics:
Cell and gene therapy
